Evidence map›Paper›PMID 33172974›Full record

ArticleMolecular cancer research : MCR2021

5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells.

Brian M Reilly, Timothy Luger, Soo Park, Chan-Wang Jerry Lio, Edahí González-Avalos, Emily C Wheeler, Minjung Lee, Laura Williamson, Tiffany Tanaka, Dinh Diep and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Brian M ReillyBiomedical Sciences Graduate Program, University of California San Diego, La Jolla, California.ORCID https://orcid.org/0000-0001-7418-1359
Timothy LugerMoores Cancer Center, University of California San Diego, La Jolla, California.
Soo ParkMoores Cancer Center, University of California San Diego, La Jolla, California.
Chan-Wang Jerry LioDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, California.
Edahí González-AvalosDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, California.
Emily C WheelerBiomedical Sciences Graduate Program, University of California San Diego, La Jolla, California.
Minjung LeeCenter for Epigenetics and Disease Prevention, Texas A&M University Health Science Center, Houston, Texas.
Laura WilliamsonDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, California.
Tiffany TanakaMoores Cancer Center, University of California San Diego, La Jolla, California.
Dinh DiepDepartment of Bioengineering, University of California San Diego, La Jolla, California.
Kun ZhangDepartment of Bioengineering, University of California San Diego, La Jolla, California.ORCID https://orcid.org/0000-0002-7596-5224
Yun HuangCenter for Epigenetics and Disease Prevention, Texas A&M University Health Science Center, Houston, Texas.
Anjana RaoMoores Cancer Center, University of California San Diego, La Jolla, California.
Rafael BejarBiomedical Sciences Graduate Program, University of California San Diego, La Jolla, California. rabejar@ucsd.edu.
University of California San Diego · USLa Jolla Institute for Immunology · USLa Jolla Bioengineering Institute · USThe University of Texas Health Science Center at Houston · US

Funding

The TET-DNMT-ASXL1-OGT axis: relevance to clonal hematopoiesis, heterochromatin integrity and cancerR35CA210043 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Anjana Rao · 2016 to 2026
$10.6M
Characterization of Genetic Abnormalities in MDS and Their Clinical ImpactK08DK091360 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BEJAR, RAFAEL · 2012 to 2016
$789k
NCI NIH HHS R35 CA210043NIDDK NIH HHS K08 DK091360
6 · The paper itself

Abstract

DNA methyltransferase inhibitors (DNMTI) like 5-Azacytidine (5-Aza) are the only disease-modifying drugs approved for the treatment of higher-risk myelodysplastic syndromes (MDS), however less than 50% of patients respond, and there are no predictors of response with clinical utility. Somatic mutations in the DNA methylation regulating gene

Indexed as

AzacitidineCell DifferentiationDioxygenasesDNA-Binding ProteinsGene ExpressionHumansLeukemia, Erythroblastic, AcuteAzacitidineDioxygenasesDNA-Binding ProteinsTET2 protein, human

Identifiers

PMID33172974
PMCPMC7925369
OpenAlexW3105068414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.